References
- Valgimigli M, Bueno H, Byrne RA, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017 [[cited 2022 Jul 23]];39:213–254. InternetAvailable from https://pubmed.ncbi.nlm.nih.gov/28886622/
- Collet JP, Thiele H, Barbato E, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2020;42:1289–1367. https://pubmed.ncbi.nlm.nih.gov/32860058/ InternetAvailable from: [cited 2022 Mar 12].
- Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2018;40:87–165. https://pubmed.ncbi.nlm.nih.gov/30165437/ InternetAvailable from: [cited 2022 Jul 23].
- Lawton JS, Tamis-Holland JE, Bangalore S, et al. ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021 [[cited 2023 May 13]];145:E4–E17. InternetAvailable from https://pubmed.ncbi.nlm.nih.gov/34882436/
- Gargiulo G, Esposito G, Avvedimento M, et al. Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-Segment-elevation myocardial infarction: primary results of the FABOLUS-FASTER Trial. Circulation 2020;142:441–454. DOI:10.1161/CIRCULATIONAHA.120.046928. https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.120.046928 InternetAvailable from: [cited 2022 Aug 1].
- Gragnano F, Spirito A, Corpataux N, et al. Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. EuroIntervention. 2021;17(11):E898–E909. DOI:10.4244/EIJ-D-21-00181. [cited 2022 Aug 1]. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/34105513/
- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. [cited 2023 May 13]. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/19717846/
- Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. [cited 2023 May 13]. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/17982182/
- Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–2166. [cited 2023 May 13]. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/25399658/
- Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–1800. [cited 2023 May 13]. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/25773268/
- Leonardi S, Gragnano F, Carrara G, et al. Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized with Acute Coronary Syndromes. J Am Coll Cardiol. 2021;77(4):375–388. DOI:10.1016/j.jacc.2020.11.046. [cited 2022 Aug 1]. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/33509394/
- Gragnano F, Heg D, Franzone A, et al. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. Eur Heart J Cardiovasc Pharmacother. 2022;8(1):28–38. DOI:10.1093/ehjcvp/pvaa106. [cited 2023 May 13]. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/32941620/
- Galli M, Franchi F, Rollini F, et al. Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. Trends Cardiovasc Med. 2021. [cited 2022 Mar 12]; Available from. Internet https://pubmed.ncbi.nlm.nih.gov/34936903/
- Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y 12 receptor inhibitor treatment in percutaneous coronary intervention. JACC: Cardiovasc Interv. InternetAvailable from. 2019. [cited 2022 Mar 12]. 12(16):1521–1537. https://pubmed.ncbi.nlm.nih.gov/31202949/
- Marcucci Rossella, Berteotti Martina, Gragnano Felice, et al. Monitoring antiplatelet therapy: where are we now? Journal of Cardiovascular Medicine J Cardiovasc Med (Hagerstown). 2023;24(Suppl. 1):e24–e35. . [Internet]. : https://journals.lww.com/jcardiovascularmedicine/Fulltext/9900/Monitoring_antiplatelet_therapy__where_are_we_now_.79.aspx. DOI:10.2459/JCM.0000000000001406. 1 Apr 2023.
- Rodriguez F, Harrington RA, Longo DL. Management of antithrombotic therapy after acute coronary syndromes. N Engl J Med. 2021;384(5):452–460. [cited 2022 Mar 12]. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/33534976/
- Cao D, Gragnano F. Clopidogrel monotherapy after 1-month DAPT in diabetic patients undergoing PCI: is less always more? JACC: Cardiovasc Interv. 2023;16(1):32–35. DOI:10.1016/j.jcin.2022.10.044. [cited 2023 May 13] 2023. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/36599585/
- Pakala R, Waksman R. Currently available methods for platelet function analysis: advantages and disadvantages. Cardiovasc Revasc Med. 2011;12(5):312–322. [cited 2022 Mar 12]. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/21036109/
- Jeong YH, Bliden KP, Antonino MJ, et al. Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. Am Heart J. 2012;164(1):35–42. [cited 2022 Mar 12]. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/22795280/
- Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388(10055):2015–2022. [cited 2022 Jul 15]. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/27581531/
- Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. InternetAvailable from. 2017. [cited 2022 Mar 12]. 390(10104);1747–1757. https://pubmed.ncbi.nlm.nih.gov/28855078/
- Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. [cited 2022 Nov 30]. 2019;381:1621–1631. InternetAvailable from. 17. https://pubmed.ncbi.nlm.nih.gov/31479209/
- Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. [cited 2022 Apr 16]. 2017;38:3070–3078. InternetAvailable from. 41. https://pubmed.ncbi.nlm.nih.gov/28510646/
- Kim HS, Kang J, Hwang D, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet InternetAvailable from. [cited 2022 Jul 15] 2020;396(10257):1079–1089. https://pubmed.ncbi.nlm.nih.gov/32882163/
- Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet InternetAvailable from. [cited 2022 Apr 16] 2021;398(10308):1305–1316. https://pubmed.ncbi.nlm.nih.gov/34627490/
- Galli M, Benenati S, Franchi F, et al. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Eur Heart J. [cited 2022 Apr 16]. 2022;43:959–967. InternetAvailable from. 10. https://pubmed.ncbi.nlm.nih.gov/34918066/
- Patti G, Grisafi L, Spinoni EG, et al. Safety and efficacy of selective, clopidogrel-based strategies in acute coronary syndrome: a study-level meta-analysis. Thromb Haemost. 2022. [cited 2022 Sep 26]; Available from. Internet https://pubmed.ncbi.nlm.nih.gov/35436797/
- Kang J, Rizas KD, Woo Park K, et al. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis. Eur Heart J. [InternetAvailable from]. 2023 [[cited 2023 May 13]];44:1360–1370. DOI:10.1093/eurheartj/ehac829.
- Kuno T, Fujisaki T, Shoji S, et al. Comparison of unguided de-escalation versus guided selection of dual antiplatelet therapy after acute coronary syndrome: a systematic review and network meta-analysis. Circ Cardiovasc Interv. 2022;15 [[cited 2022 Jul 30]]. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/35899618
- Laudani C, Greco A, Occhipinti G, et al. Short duration of DAPT versus De-escalation after percutaneous coronary intervention for acute coronary syndromes. JACC: Cardiovasc Interv InternetAvailable from. [cited 2022 Nov 30] 2022;15(3):268–277. https://pubmed.ncbi.nlm.nih.gov/35144783/
- Corpataux N, Spirito A, Gragnano F, et al. Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. Eur Heart J. [cited 2022 Aug 1]. 2020;41:3743–3749. DOI:10.1093/eurheartj/ehaa671. InternetAvailable from. 38. https://pubmed.ncbi.nlm.nih.gov/33029615/
- Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. [cited 2023 May 13]. 2017;389:1025–1034. InternetAvailable from. 10073. https://pubmed.ncbi.nlm.nih.gov/28290994/
- Valgimigli M, Gragnano F, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021 [[cited 2022 Jul 23]];373:n1332. DOI:10.1136/bmj.n1332. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/34135011/
- Gragnano F, Mehran R, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions. J Am Coll Cardiol. [cited 2023 May 13] 2023. 2023;81:537–552. DOI:10.1016/j.jacc.2022.11.041. InternetAvailable from. 6. https://pubmed.ncbi.nlm.nih.gov/36754514/